Takeda nominates Kimberly Reed and Dr. John Maraganore for election to its Board as Independent Directors

– JAPAN, Tokyo –  Takeda (TYO: 4502 | NYSE: TAK) today announced the nominations of Kimberly Reed and Dr. John Maraganore (Ph.D.) for their elections to its Board as new independent external directors at the AGM on June 29, 2022.

They should succeed Toshiyuki Shiga and Shiro Kuniya who will retire.

In addition, Masami Iijima will be appointed as the new chair of the Board, succeeding Masahiro Sakane, who will also retire.

About Kimberly A. Reed

Kimberly Reed most recently served as Chairman of the Board of Directors, President, and CEO of the Export-Import Bank of the United States, the nation’s official $135 billion export credit agency, where she worked to help companies succeed in the competitive global marketplace. She previously served as President of the International Food Information Council Foundation where she focused on agriculture, nutrition, and health issues; Senior Advisor to U.S. Treasury Secretaries Henry Paulson and John Snow; CEO of the Community Development Financial Institutions Fund; and Counsel to three committees with the U.S. Congress where she conducted oversight and investigations. Ms. Reed currently serves on the Board of Directors of Momentus (NASDAQ: MNTS) and is a Distinguished Fellow at the Council on Competitiveness. Recognized as one of the 100 Women Leaders in STEM, Ms. Reed has served on numerous non-profit boards, including the Alzheimer’s Association, and is a member of the Council on Foreign Relations and Indiana University School of Public Health-Bloomington Dean’s Alliance. She holds a J.D. from West Virginia University College of Law and a B.S. in Biology and a B.A. in Government from West Virginia Wesleyan College and is a National Association of Corporate Directors Certified Director.

Ms. Reed said, “I am honored to be a candidate to join Takeda’s Board of Directors at this significant moment in the company’s proud history. I have deep respect for Takeda’s strong leadership in biopharmaceutical science, values-led growth, and sustainability. I welcome the opportunity to help deliver on Takeda’s promise of better health and life-changing treatments for people all around the world.”

About Dr. John Maraganore

Dr. John Maraganore is a pioneering executive with more than three decades of experience in the pharmaceutical industry. He served as CEO and director of Alnylam Pharmaceuticals for nearly 20 years and retired at the end of 2021. From June 2017 to May 2019, he was the chair of the Biotechnology Industry Organization. Before Alnylam, Dr. Maraganore served as an officer and member of the management team of Millennium Pharmaceuticals, Inc. Before Millennium, he served as director of molecular biology and director of market and business development at Biogen, Inc. At Biogen, he invented and led the discovery and development of bivalirudin for injection. Dr. Maraganore has Ph.D. and M.S. degrees in Biochemistry and Molecular Biology from the University of Chicago.

Dr. Maraganore said, “I admire Takeda’s transformation journey into a top-tier global pharmaceutical company and, if approved, I look forward to working alongside the rest of the Board to support the company’s mission to deliver breakthrough medicines through its leading science and commercial capabilities.”

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people, and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving the quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information: https://www.takeda.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.